These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1057 related articles for article (PubMed ID: 9191605)
1. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605 [TBL] [Abstract][Full Text] [Related]
2. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Zaidi TS; Priebe GP; Pier GB Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743 [TBL] [Abstract][Full Text] [Related]
3. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231 [TBL] [Abstract][Full Text] [Related]
4. Secretory IgA inhibits Pseudomonas aeruginosa binding to cornea and protects against keratitis. Masinick SA; Montgomery CP; Montgomery PC; Hazlett LD Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):910-8. PubMed ID: 9112987 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection. Moon MM; Hazlett LD; Hancock RE; Berk RS; Barrett R Invest Ophthalmol Vis Sci; 1988 Aug; 29(8):1277-84. PubMed ID: 2843483 [TBL] [Abstract][Full Text] [Related]
6. Evidence for TIMP-1 protection against P. aeruginosa-induced corneal ulceration and perforation. Kernacki KA; Barrett R; Hazlett LD Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3168-76. PubMed ID: 10586939 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. Colwell DE; Michalek SM; Briles DE; Jirillo E; McGhee JR J Immunol; 1984 Aug; 133(2):950-7. PubMed ID: 6203984 [TBL] [Abstract][Full Text] [Related]
8. Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vaccination with lipopolysaccharide endotoxins and proteases. Kreger AS; Lyerly DM; Hazlett LD; Berk RS Invest Ophthalmol Vis Sci; 1986 Jun; 27(6):932-9. PubMed ID: 3519522 [TBL] [Abstract][Full Text] [Related]
9. Immunization with homologous Pseudomonas aeruginosa pili protects against ocular disease. Rudner XL; Berk RS; Hazlett LD Reg Immunol; 1993; 5(5):245-52. PubMed ID: 7908533 [TBL] [Abstract][Full Text] [Related]
10. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845 [TBL] [Abstract][Full Text] [Related]
11. Lecithin-bound superoxide dismutase in the prevention of neutrophil-induced damage of corneal tissue. Matsumoto K; Shimmura S; Goto E; Saito K; Takeuchi T; Miyajima S; Negi A; Tsubota K Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):30-5. PubMed ID: 9430542 [TBL] [Abstract][Full Text] [Related]
12. Oral vaccination and multivalent vaccine against Pseudomonas aeruginosa keratitis. Gerke JR; Nelson JS Invest Ophthalmol Vis Sci; 1977 Jan; 16(1):76-80. PubMed ID: 832968 [TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of immune gamma-globulin fraction on protection by antibiotic against corneal ulcers in experimental mice infected with Pseudomonas aeruginosa. Kawaharajo K; Homma JY Jpn J Exp Med; 1976 Jun; 46(3):155-65. PubMed ID: 822190 [TBL] [Abstract][Full Text] [Related]
14. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis. Faezi S; Sattari M; Mahdavi M; Roudkenar MH Burns; 2011 Aug; 37(5):865-72. PubMed ID: 21334822 [TBL] [Abstract][Full Text] [Related]
15. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
16. Human IgG but not IgM antibodies can protect mice from the challenge with live O6 Escherichia coli. Pontes GN; Massironi SG; Arslanian C; Palmeira P; Carneiro-Sampaio MM; Nagao AT Scand J Immunol; 2005 Oct; 62(4):353-60. PubMed ID: 16253122 [TBL] [Abstract][Full Text] [Related]
17. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Moriyama K; Wiener-Kronish JP; Sawa T Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258 [TBL] [Abstract][Full Text] [Related]
18. Immunoprotection by monoclonal antibodies to the porins and lipopolysaccharide of Salmonella typhimurium. Singh SP; Williams YU; Benjamin WH; Klebba PE; Boyd D Microb Pathog; 1996 Oct; 21(4):249-63. PubMed ID: 8905614 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. Dunn DL; Bogard WC; Cerra FB Surgery; 1985 Aug; 98(2):283-90. PubMed ID: 3895540 [TBL] [Abstract][Full Text] [Related]
20. Experimental chronic Pseudomonas aeruginosa lung infection in rats. Non-specific stimulation with LPS reduces lethality as efficiently as specific immunization. Lange KH; Hougen HP; Høiby N; Fomsgaard A; Rygaard J; Johansen HK APMIS; 1995 May; 103(5):367-74. PubMed ID: 7654361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]